Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026
Autolus Therapeutics (Nasdaq: AUTL) will release first quarter 2026 financial results and operational highlights before U.S. market open on May 14, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL) will release first quarter 2026 financial results and operational highlights before U.S. market open on May 14, 2026.
Management will host a conference call and webcast on May 14, 2026 at 8:30am EDT / 1:30pm BST to discuss results and provide a general business update; preregistration is required for dial‑in access and PINs.
Details
News Market Reaction – AUTL
On May 5, the day this news came out, AUTL closed 4.46% above the previous close.
Data tracked by StockTitan Argus for the May 5 session.
Key Figures
- Shelf capacity
- $150,000,000
- Form S-3 shelf filed April 10, 2026
- Ordinary shares
- 266,143,286 shares
- Issued as of December 31, 2025 per S-3
- Registered ADS resale
- 54,584,250 ADSs
- Resale registration for selling securityholders
- Workforce reduction
- 13%
- Restructuring initiative announced April 29, 2026
- Restructuring charges
- $8 million
- Estimated total related to workforce reduction
- OpEx reduction
- $15 million annually
- Expected operating expense savings from 2027
- 2026 AUCATZYL guidance
- $120–$135 million
- Projected 2026 net product revenue
- Cash balance
- $300.7 million
- Cash, equivalents and securities as of December 31, 2025
Previous Conferences,earnings date Reports
-
Announcement of Q4 and full-year 2025 results timing and conference call logistics.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and GAITHERSBURG, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its first quarter 2026 financial results and operational highlights before open of U.S. markets on Thursday, May 14, 2026.
Management will host a conference call and webcast at 8:30am EDT / 1:30pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.